Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease.


Chronic graft-versus-host disease (GVHD) is the most common late complication of allogeneic bone marrow transplantation (BMT). The sclerodermatous form of the disease is often refractory to standard treatment modalities. Based on reports of response to etretinate, a synthetic retinoid, among patients with scleroderma, we have added etretinate to the… (More)

3 Figures and Tables


  • Presentations referencing similar topics